scholarly journals Effect of Epiretinal Membrane Peeling on Intravitreal Aflibercept Therapy Response for Polypoidal Choroidal Vasculopathy: A Case Report

2018 ◽  
Author(s):  
Aslı Kırmacı
Keyword(s):  
Case Report ◽  
Epiretinal Membrane ◽  
Polypoidal Choroidal Vasculopathy ◽  
Therapy Response ◽  
Membrane Peeling ◽  
Intravitreal Aflibercept ◽  
Choroidal Vasculopathy

scholarly journals Activation of quiescent polypoidal choroidal vasculopathy after membrane peeling vitrectomy for epiretinal membrane: a case report

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Yuelin Wang ◽  
Zhe Chen ◽  
Weihong Yu ◽  
Youxin Chen
Keyword(s):  
Epiretinal Membrane ◽  
Polypoidal Choroidal Vasculopathy ◽  
Unusual Case ◽  
Therapeutic Process ◽  
Intravitreal Ranibizumab ◽  
Case Presentation ◽  
Membrane Peeling ◽  
Corrected Visual Acuity ◽  
Choroidal Vasculopathy ◽  
Ranibizumab Treatment

Abstract Background Regular membrane peeling vitrectomy for epiretinal membrane (ERM) patients seldom causes large pigment epithelial detachment (PED). We presented an unusual case of the activation of quiescent polypoidal choroidal vasculopathy (PCV) after membrane peeling vitrectomy for ERM, with an uneven therapeutic process. Case presentation A 75-year-old female patient complained of metamorphopsia in her left eye for 2 years. Her best-corrected visual acuity was 20/160 with a moderate nuclear cataract. An irregular ERM and slight PED were shown in optical coherence tomography (OCT). No obvious orange-red lesion was detected. The patient underwent vitrectomy + ERM peeling + cataract surgery. After the operation, large PED emerged, and indocyanine green angiography (ICGA) confirmed PCV. Four monthly injections of intravitreal ranibizumab were administered, but PED persisted. After focal laser therapy targeted to the polyps combined with ranibizumab treatment, PED was absorbed. Conclusions Careful evaluation for PCV before membrane peeling vitrectomy for ERM is important, as indolent PCV may be activated postoperatively. Anti-VEGF therapy accompanied by laser photocoagulation may be more effective for PCV polyps located away from the fovea.

scholarly journals Idiopathic Polypoidal Choroidal Vasculopathy – A Case Report

2016 ◽  
Vol 1 (1) ◽  
pp. 1-4
Author(s):  
Rahul Gupta ◽  
Shairin Jahan ◽  
Gargi Nagpal ◽  
Naheed Akhtar ◽  
Abdul Waris
Keyword(s):  
Case Report ◽  
Polypoidal Choroidal Vasculopathy ◽  
Choroidal Vasculopathy

scholarly journals Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy in the PLANET Study

2018 ◽  
Vol 136 (7) ◽  
pp. 786 ◽  
Author(s):  
Won Ki Lee ◽  
Tomohiro Iida ◽  
Yuichiro Ogura ◽  
Shih-Jen Chen ◽  
Tien Yin Wong ◽  
...  
Keyword(s):  
Polypoidal Choroidal Vasculopathy ◽  
Efficacy And Safety ◽  
Intravitreal Aflibercept ◽  
Choroidal Vasculopathy

Short-Term Efficacy of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy

2015 ◽  
Vol 56 (11) ◽  
pp. 1728 ◽  
Author(s):  
Heon Yang ◽  
Hye Min Jeon ◽  
Sang Won Kim ◽  
Hee Seong Yoon ◽  
Woo Seok Choae
Keyword(s):  
Polypoidal Choroidal Vasculopathy ◽  
Short Term ◽  
Term Efficacy ◽  
Intravitreal Aflibercept ◽  
Choroidal Vasculopathy

scholarly journals Efficacy of intravitreal aflibercept injections for Japanese patients with polypoidal choroidal vasculopathy

2017 ◽  
Vol Volume 11 ◽  
pp. 797-802 ◽  
Author(s):  
Akira Arakawa ◽  
Maiko Inoue ◽  
Shimpei Sato ◽  
Shin Yamane ◽  
Kazuaki Kadonosono
Keyword(s):  
Polypoidal Choroidal Vasculopathy ◽  
Japanese Patients ◽  
Intravitreal Aflibercept ◽  
Choroidal Vasculopathy

Changes of choroidal structure after intravitreal aflibercept therapy for polypoidal choroidal vasculopathy

2016 ◽  
Vol 101 (1) ◽  
pp. 56-61 ◽  
Author(s):  
Erina Daizumoto ◽  
Yoshinori Mitamura ◽  
Hiroki Sano ◽  
Kei Akaiwa ◽  
Masanori Niki ◽  
...  
Keyword(s):  
Polypoidal Choroidal Vasculopathy ◽  
Intravitreal Aflibercept ◽  
Choroidal Structure ◽  
Choroidal Vasculopathy

Intravitreal Aflibercept and Ranibizumab Injections for Polypoidal Choroidal Vasculopathy

2016 ◽  
Vol 165 ◽  
pp. 1-6 ◽  
Author(s):  
Han Joo Cho ◽  
Kyoung Min Kim ◽  
Hyoung Seok Kim ◽  
Jung Il Han ◽  
Chul Gu Kim ◽  
...  
Keyword(s):  
Polypoidal Choroidal Vasculopathy ◽  
Intravitreal Aflibercept ◽  
Choroidal Vasculopathy

scholarly journals Long-Term Follow-Up of Polypoidal Choroidal Vasculopathy Secondary to Angioid Streaks Treated by Intravitreal Aflibercept and Ranibizumab

2017 ◽  
Vol 8 (1) ◽  
pp. 221-231 ◽  
Author(s):  
James G. Wong ◽  
Katherine Yu Qian
Keyword(s):  
Polypoidal Choroidal Vasculopathy ◽  
Angioid Streaks ◽  
Case Review ◽  
Retrospective Case ◽  
Treat And Extend ◽  
Anti Vegf ◽  
Intravitreal Aflibercept ◽  
Choroidal Vasculopathy

Purpose: Angioid streaks (AS) are dehiscences in Bruch’s membrane that may be idiopathic or associated with numerous systemic illnesses. Polypoidal choroidal vasculopathy (PCV) is an underdiagnosed exudative chorioretinopathy often characterised by serosanguineous detachments of the pigmented epithelium. The use of the anti-VEGF agents ranibizumab and aflibercept in the management of PCV secondary to AS has not been previously documented. We report 3 patients with active PCV secondary to AS, 1 of which had a family history of PCV secondary to AS, not previously reported in the literature. All patients were symptomatic and treated with intravitreal anti-VEGF therapy with and without combination photodynamic therapy (PDT). Methods: This is a long-term retrospective case review of 3 eyes of 3 patients with AS and clinical features of PCV. The patients were examined using fundoscopy, spectral domain optical coherence tomography, fluorescein angiography, and indocyanine green angiography. All patients were managed with intravitreal anti-VEGF using a treat-and-extend protocol according to specific retreatment criteria. One patient had 1 session of PDT in combination with anti-VEGF injections. Results: The mean follow-up time in all patients was 4 years. In all 3 cases, the treatment resulted in improved visual acuity and regression of active PCV lesions with a longer duration between injections. Conclusion: The treat-and-extend protocol with intravitreal aflibercept or ranibizumab with or without PDT is effective and safe for PCV secondary to AS.

Sign in / Sign up

Export Citation Format

Share Document